French pharmaceutical giant Sanofi has announced a major leadership transition, with Belén Garijo set to take over as CEO, replacing Paul Hudson after his six-year tenure.
Strategic Drivers Behind the Shift
The decision to transition leadership comes as Sanofi navigates a complex operational environment:
-
Market Performance: The company’s Paris-listed shares have plummeted by over 20% since early 2025.
-
U.S. Regulatory Headwinds: Recent shifts in vaccine policy and immunization recommendations in the United States have pressured Sanofi’s extensive vaccine portfolio.
-
Pipeline Setbacks: Despite heavy R&D investment, several key drug candidates, including treatments for multiple sclerosis and a specialized E. coli vaccine, have recently faced trial failures or regulatory rejections.
The New Leadership Profile
Belén Garijo brings a wealth of industry expertise back to Sanofi:
-
Background: Prior to her role as CEO of Merck KGaA since 2021, she spent 15 years in senior leadership positions within Sanofi.
-
Milestones: Garijo was notably the first woman to lead a major blue-chip company in Germany.
-
Primary Mandate: Starting April 29, 2026, her mission will focus on strengthening R&D governance, enhancing productivity, and accelerating innovation to prepare for upcoming patent expirations of blockbuster therapies like Dupixent.
Until Garijo formally assumes her duties, Olivier Charmeil will serve as the interim leader. Industry analysts are closely watching to see if this leadership pivot can stabilize investor confidence and revitalize the company’s clinical pipeline.